U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry UNKNOWN
Molecular Formula C19H25NO2
Molecular Weight 299.408
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NYLIDRIN

SMILES

CC(CCc1ccccc1)NC(C)C(c2ccc(cc2)O)O

InChI

InChIKey=PTGXAUBQBSGPKF-UHFFFAOYSA-N
InChI=1S/C19H25NO2/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17/h3-7,10-15,19-22H,8-9H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C19H25NO2
Molecular Weight 299.408
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://eci2012.net/product/arlidin/

Nylidrin (Buphenine, Arlidin) is a beta-adrenergic agonist. Nylidrin causes peripheral vasodilation, a positive inotropic effect, and increased gastric volume of gastric juice. It is used in the treatment of peripheral vascular disorders and premature labor. In peripheral vascular disorders, Arlidin (nylidrin HCl) increases walking ability and promotes healing of trophic ulcers. Nylidrin hydrochloride acts predominantly by beta-receptor stimulation. Beta stimulation with nylidrin has been demonstrated in a variety of isolated tissues from rabbits, guinea pigs and dogs. It has been shown to dilate arterioles in skeletal muscle and to increase cardiac output in the anesthetized dog and cat and in unanesthetized man. An increase in cerebral blood flow and a decrease in vascular resistance has also been reported. The result of this combination of actions is a greater blood supply to ischemic tissues, with usually minimal change in blood pressure. Arlidin may be of benefit in elderly patients with mild to moderate symptoms that are commonly associated with organic mental disorders. Short-term (3 months’ duration) and long-term (12 months’ duration) clinical studies have demonstrated a modest improvement in ability to perform general activities of daily living, self-care and in a capability for social interactions. The mechanism whereby nylidrin may provide relief of selected symptoms in some elderly patients with organic brain disorders is not known.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Arlidin

Approved Use

May be of benefit in elderly patients with mild to moderate symptoms that are commonly associated with organic mental disorders.
Primary
Arlidin

Approved Use

Peripheral vascular disease, intermittant claudication, thrombophlebitis, TAO, frost bite, nocturnal leg cramps.
Doses

Doses

DosePopulationAdverse events​
120 mg single, oral
Overdose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Sources:
unknown, 14 years
Health Status: unknown
Age Group: 14 years
Sex: F
Sources:
Other AEs: Chest pain, Headache...
Other AEs:
Chest pain (1 patient)
Headache (1 patient)
Flushing (1 patient)
Shortness of breath (1 patient)
Sources:
6 mg 2 times / day multiple, oral
Dose: 6 mg, 2 times / day
Route: oral
Route: multiple
Dose: 6 mg, 2 times / day
Sources:
unhealthy, 32 years
Health Status: unhealthy
Age Group: 32 years
Sex: M
Sources:
50 mg/min multiple, intravenous
Dose: 50 mg/min
Route: intravenous
Route: multiple
Dose: 50 mg/min
Sources:
pregnant
Health Status: pregnant
Sex: F
Sources:
AEs

AEs

AESignificanceDosePopulation
Chest pain 1 patient
120 mg single, oral
Overdose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Sources:
unknown, 14 years
Health Status: unknown
Age Group: 14 years
Sex: F
Sources:
Flushing 1 patient
120 mg single, oral
Overdose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Sources:
unknown, 14 years
Health Status: unknown
Age Group: 14 years
Sex: F
Sources:
Headache 1 patient
120 mg single, oral
Overdose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Sources:
unknown, 14 years
Health Status: unknown
Age Group: 14 years
Sex: F
Sources:
Shortness of breath 1 patient
120 mg single, oral
Overdose
Dose: 120 mg
Route: oral
Route: single
Dose: 120 mg
Sources:
unknown, 14 years
Health Status: unknown
Age Group: 14 years
Sex: F
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Development and use of a computer program to detect potentially inappropriate prescribing in older adults residing in Canadian long-term care facilities.
2002 Oct 14
Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials.
2003 Sep
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Sample Use Guides

The recommended dose of nylidrin is 12 mg to 24 mg daily in 3 or 4 divided doses for certain types of mental disorders. For blood vessel disorders of the legs, the recommended adult dose is 12 mg to 48 mg daily in 3 to 4 divided doses.
Route of Administration: Oral
In Vitro Use Guide
Nylidrin was a potent (IC50 = 0.18 uM) antagonist of rat NR1A/2B receptors expressed in Xenopus oocytes
Substance Class Chemical
Created
by admin
on Sat Jun 26 05:29:44 UTC 2021
Edited
by admin
on Sat Jun 26 05:29:44 UTC 2021
Record UNII
695DKH33EI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NYLIDRIN
HSDB   MI   VANDF  
Common Name English
P-HYDROXY-.ALPHA.-(1-((1-METHYL-3-PHENYLPROPYL)AMINO)ETHYL)BENZYL ALCOHOL
Common Name English
BUPHENIN
Common Name English
BENZENEMETHANOL, 4-HYDROXY-.ALPHA.-(1-((1-METHYL-3-PHENYLPROPYL)AMINO)ETHYL)-
Systematic Name English
BUPHENINE
INN   WHO-DD  
INN  
Official Name English
NYLIDRIN [VANDF]
Common Name English
BUPHENINE [INN]
Common Name English
NYLIDRIN [MI]
Common Name English
BUPHENINE [WHO-DD]
Common Name English
NYLIDRIN [HSDB]
Common Name English
Classification Tree Code System Code
WHO-ATC C04AA02
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
WHO-ATC G02CA02
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
NCI_THESAURUS C48149
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
WHO-VATC QC04AA02
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
WHO-VATC QG02CA02
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
Code System Code Type Description
RXCUI
7595
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL114655
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
HSDB
3137
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
DRUG CENTRAL
1976
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
WIKIPEDIA
Nylidrin
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
MESH
D009756
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
NCI_THESAURUS
C81642
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
ECHA (EC/EINECS)
207-182-2
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
DRUG BANK
DB06152
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
EVMPD
SUB05981MIG
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
MERCK INDEX
M8091
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY Merck Index
FDA UNII
695DKH33EI
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
EPA CompTox
447-41-6
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
CAS
447-41-6
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
PUBCHEM
4567
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
INN
461
Created by admin on Sat Jun 26 05:29:44 UTC 2021 , Edited by admin on Sat Jun 26 05:29:44 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY